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of IRP reforms as we found that even small changes to reference baskets used in 
IRP can lead to large negative financial impacts for pharmaceutical manufactures.
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in THe finnisH reimbursemenT sysTem
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Objectives: In most western countries it is a prerequisite before a new drug is 
approved into the reimbursement system that its cost-effectiveness has been dem-
onstrated. The pricing authorities’ assessment of the cost-effectiveness is usually 
based on a health economic evaluation required from the applicant. In Finland 
these evaluations have been obligatory since 1998. The objective of this study is to 
assess the present quality of these economic evaluations. MethOds: This study 
is based on a random sample of 13 economic evaluations submitted with price 
applications in Finland in 2012. These evaluations were assessed using a structured 
questionnaire with 25 different items. The items assessed include e.g. the choice 
of comparator, the method of analysis, the structure of the model, the estimation 
costs and health effects and the assessment of uncertainty. Results: Only two of 
the 13 evaluations were reliable enough for their results to be used as such in the 
pricing and reimbursement decision. In seven evaluations the results were of some 
use in the decision making. Among the reasons limiting their usefulness were that 
they contained uncertain assumptions, that some costs items were excluded from 
the analysis, and that the effectiveness of the treatments was based mainly on 
assumptions. Four economic evaluations could not be used in the decision making 
at all because the comparator was wrong, the effectiveness estimates were biased, 
or there was a lot of uncertainty attached to the key parameters (effectiveness, 
quality of life and costs). cOnclusiOns: There is still much to be improved in 
the quality of the submitted economic evaluations. This need for improvements is 
highlighted by the fact that the era of prolonged austerity has made it all the more 
important that only drugs with an acceptable cost-effectiveness ratio are accepted 
into the reimbursement system.
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Objectives: To assess the effects of policy and institutional changes on the total 
Time to Reimbursement (tTTR) of innovative pharmaceutical products in Canada. 
Such changes include: the removal of criteria for “pre-NOC” drugs; queuing at CDR 
as its capacity to process submissions is stretched; and the emergence of the pan-
Canadian Pricing Alliance (pCPA), which negotiates with manufacturers on behalf 
of drug plans. MethOds: Using our proprietary CDR Tracker® database we assessed 
the tTTR, i.e. time from receipt of Notice of Compliance (NOC) to provincial reim-
bursement, for all CDR-reviewed drugs reimbursed by the Ontario Public Drug Plan. 
We separately examined the responsibilities of pharma manufacturers, CDR and 
the provinces themselves. We analyzed the Time to Submission, (TTS), i.e. NOC date 
to CDR submission date, Time to Recommendation (TTRec), i.e. CDR submission 
date to CDR recommendation date, and the Time to Decision (TTD) by the drug 
plan, i.e. recommendation date to Ontario formulary decision date. We assessed 
the tTTR for each year of CDR’s existence to identify changes of importance to 
manufacturers. Results: Removal of criteria for pre-NOC submissions increased 
their number: 17 pre-NOC submissions have occurred in months since the policy 
change, compared to 4 in total previously. Average TTS fell from 217 days to 151 days 
for drugs submitted before and after the change. TTRec prior to the queuing period 
was 203 ± 40 days. Since queuing was introduced this has increased to 214 ± 18 days. 
TTD has steadily declined over time and sharply since the arrival of pCPA. tTTR 
rose steadily from the beginning of CDR and fell sharply with the introduction of 
pCPA. cOnclusiOns: pCPA and CDR’s efforts have attentuated the consequences 
of queuing so far, though the full effect of the large and growing number of drugs 
currently in queue at CDR remains to be seen.
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Objectives: Numerous studies have examined prescription utilization and medi-
cation adherence using continuous enrollment criteria with claims data. Benefit 
design changes may have an impact on both measures. The purpose of this analysis 
was to indentify the multiple changes of benefit plan designs that occurred in a 
commercially insured population continuously enrolled for 30 months. MethOds: 
Retrospective study examining eligibility data and health plan benefit design 
records. Commercially insured beneficiaries aged 18 or older and enrolled from 
January 1st, 2011 through June 30th, 2013 were included. The benefit designs for 
all beneficiaries were identified from administrative records. Results: 2,489,106 
beneficiaries met enrollment criteria. Approximately 12% (289,159 beneficiaries) 
experienced at least one change in retail, mail, or Extended Supply Network (ESN) 
benefit design at some point during their enrollment. 248,734 beneficiaries (86.0%) 
experienced changes in retail benefit design; 261,526 beneficiaries (90.4%) expe-
rienced changes in mail benefit design; 97,548 beneficiaries (33.7%) experienced 
changes in ESN benefit design. Among the retail changes, 44,134 beneficiaries 
(17.7%) had a change in tier structure [23,490 with an increased in number of tiers; 
20,644 with a decreased in number of tiers]. Additionally, 10,627 beneficiaries (4.3%) 
with a retail tier copayment converted to a coinsurance design; 5,301 beneficiar-
ies (2.1%) with retail coinsurance converted to a tier copayment design; 173,760 
beneficiaries (69.9%) stayed in tier copayment design but had a change in retail 
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Objectives: To investigate the attitudes towards non-economic criteria to be 
used in resource allocation decisions in the health care sector among the Polish 
nurses. MethOds: A cross-sectional survey with pen and paper interview was 
designed. A responder was asked person trade-off question such as how many Y’s 
would be equivalent to 10 X’s. Characteristics of a hypothetical patient defined as 
X and Y varied in each of three decision making scenarios. Answers from a median 
responder were used for the estimation of disease severity and potential for health 
weights as well as aversion to inequalities in health. VAS scale was adopted. Cohen’s 
kappa coefficient and Fisher exact test were performed. Results: 100 nurses with 
on average of 15 years of professional experience were interviewed. In the first 
scenario, the utility gain was equal for both X and Y. The median responder chose 
10 and more Y to compensate for 10 X with a worse starting point. Half of partici-
pants valued health gain differently dependent on the baseline utility. In the second 
scenario, the median responder chose 10 Y to compensate for 10 X irrespective of 
X’s superior utility gain. Although X had a higher potential to benefit, only 32% of 
participants valued it more than Y. In the third scenario, the median responder 
required a greater number of subjects in program B to compensate for the lost of 
equality in the end health for both X and Y in program A. More than 65% of par-
ticipants valued health equality (program A) against greater health gain (program 
B). cOnclusiOns: Among study participants, an aversion to inequalities in end 
health was the most common. Different weightings of health gain dependent on 
the disease severity were accepted by half of participants. Majority of responders 
did not consider potential to benefit in their allocation decision.
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Objectives: The number of technologies appraised by NICE has been increas-
ing since 2007, with a steep increase between 2009 and 2010. Much of this can be 
attributed to the influx of specialty pharmaceuticals, particularly targeted oncol-
ogy therapies. Along with this increase in the number of appraisals, the rate of 
‘restricted recommendations’ and ‘non-recommendations’ has also escalated. 
Various meanings and interpretations of ‘restricted’ can be applied depending on 
the area in which the restriction is applied (e.g. patient sub-groups, line of therapy). 
This research sets out to identify recurring trends and commonalities behind prod-
ucts that have received a ‘restricted recommendation’ or ‘non-recommendation’ 
as well as standardize the term ‘restricted’ based on the impact of the appraisal on 
market access. MethOds: NICE appraisals between January, 2001 and December, 
2013 was reviewed and analyzed through simple descriptive statistics. The content 
of the appraisals were closely reviewed to identify the criteria and key elements 
driving each decision. Results of this analysis were applied in standardizing the 
term ‘restricted’ in order to identify the implications of these restrictions on market 
access. Results: NICE appraised 176 technologies from January 2001 - December 
2013 (withdrawn appraisals and re-appraisal were not included in the analysis). 
Between the time periods of 2000-2007 and 2008-2013, the average number or 
appraisals a year nearly doubled. The rate of ‘restricted recommendation’ increased 
from 12% to 36% in the same time period and the number of ‘non-recommendations’ 
increased from 10% to 23%. cOnclusiOns: Given the high cost and targeted regi-
men of specialty pharmaceuticals, (e.g. biologic oncology therapies), ability to dem-
onstrate cost-effectiveness in broad patient populations has become increasingly 
challenging, leading to higher rates of ‘restricted recommendations.’ Commonalities 
among technologies receiving ‘non-recommendations’ include use of unacceptable 
comparators, endpoints, and study durations.
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Objectives: The objective of this study was to develop a conceptual framework 
to estimate potential consequences of IRP reforms by estimating the impact if a 
European country was to include Turkey into the set of countries that it uses to 
establish the reference price. MethOds: Phase 1 consisted of obtaining evidence on 
the IRP countries using a literature review from 2011 to 2013 (WHO/HAI Systematic 
Review - May 2011) based on ECONLIT, MEDLINE and grey literature. Phase 2 con-
sisted of developing a conceptual framework and model database to summarize 
IRP designs, reference baskets, methods and updates. Model inputs for the product 
included prices, volume, and launch phase. Phase 3 consisted of building and testing 
the model from a manufacturer perspective with a variable time horizon up to 5 
years. Products from the epidermal growth factor receptor (EGFR) class were selected 
to estimate the potential effects of including Turkey into the reference basket used 
by EU countries to calculate reference rules. Results: Four peer-reviewed and a 
number of websites and white papers were identified discussing IRP related issues. 
A conceptual framework was designed considering 1) database of IRP country rules, 
2) product data, and 3) model input interface to conduct one-way sensitivity analysis 
of a simulated IRP reform. Inclusion of Turkey into the reference basket of various EU 
markets lead to large negative financial impacts for companies with EGFR products. 
The countries that lead to the largest impact were Romania and Greece. The second 
order effects such as countries that re-referenced Greece and Romania were larger 
over the 5-year time frame compared with the primary effects. cOnclusiOns: 
The proposed conceptual framework may offer another tool to estimate the impact 
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few CEDs (8%) for which there were SEP (e.g. monitoring of HbA1c for antidiabetics 
in Italy). cOnclusiOns: Although SEP are considered as not reliable from payers’ 
perspective to fund newly approved products, they have become widely acceptable 
for defining success criteria in P4P. This highlights the limitation of P4P, and more 
research would be needed to assess the actual predictive value of such endpoints. 
On the opposite, CED appears to be an appropriate tool to address payers’ uncer-
tainty as they rely on HEP for decision making.
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Objectives: Decision makers in middle income countries are using pharma-
coeconomics studies (PEs) and health technology assessments (HTAs) in pricing 
and reimbursement decisions. However, whilst many of these jurisdictions have 
local submission guidelines and local expertise, the studies themselves often use 
models developed elsewhere and elements of data from countries other than the 
jurisdiction concerned. The objectives of this study were to assess the challenges 
faced by decision makers in transferring pharmacoeconomic data and analyses 
from other jurisdictions. MethOds: We conducted an interview survey of repre-
sentatives of decision making bodies from jurisdictions in Asia, Central and Eastern 
Europe, and Latin America that had at least one year’s experience of using PEs and 
HTAs. Results: Representatives of the relevant organizations in 12 countries were 
interviewed. All 12 jurisdictions had developed official guidelines for the conduct of 
HTAs or PEs. All but one of the organizations evaluated studies submitted to them, 
but 9 also conducted studies and 7 commissioned them. Nine of the organizations 
stated that, in evaluating HTAs or PEs submitted to them, they had consulted a 
study performed in a different jurisdiction. Data on relevant treatment effect was 
generally considered more transferable than those on prices/unit costs. Views on 
the transferability of epidemiological data, data on resource use and health state 
preference values were more mixed. Eight of the respondents stated that analyses 
submitted to them had used models developed in other jurisdictions. Four of the 
organizations had a policy requiring models to be adapted to reflect local circum-
stances. cOnclusiOns: Decision makers in middle income countries were facing 
several challenges in transferring data or studies, mainly due to differences in cur-
rent standard of care, practice patterns or GDP between the developed countries 
where the majority of the studies are conducted and their own jurisdiction.
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bAckgROund: GWAS can identify targets of marketed drugs that are strongly asso-
ciated with disease(s) different from approved indication, providing opportunities 
to substantially shorten the drug development process by repositioning the drug as 
treatment for the newly identified disease, potentially yielding substantial socio-
economic benefits. Objectives: To estimate economic benefits of repositioning 
three drugs to GWAS-identified diseases MethOds: GWAS were used to identify 
denosumab (currently for osteoporosis) as possible treatment for Crohn’s disease, 
melatonin (circadian adjustment) for diabetes, and niacin (lipid-lowering) for aortic 
stenosis (AS). Economic models were constructed for the three illnesses--using data 
from Canadian registries, claims databases and clinical trials--comparing current 
management of the target illness with use of the repositioned drug. Costs (2013 CAD) 
were obtained from Medicare, Ontario Case Costing Project and price lists. Analyses 
covered each province and Canada. Results: In all three cases, the repositioned 
product was dominant over current treatment mix, even at relatively low levels of 
uptake (> 5%). With 50% uptake, in Crohn’s, denosumab would provide substan-
tial reductions in side-effects and savings of $1,619/pt, resulting in $161 million in 
annual savings across Canada; in diabetes, melatonin would save $205/pt annu-
ally, or more than $365 million for Canada, assuming equal efficacy; in AS, niacin 
would save $4.5 million in Quebec alone, largely by averting valve replacement 
surgery, providing additional benefits via reduced associated morbidity and mortal-
ity. Extensive sensitivity analyses showed these results to remain directionally the 
same except at extremely low rates of uptake or with significant increases in the 
price of the repositioned product. cOnclusiOns: Using GWAS data to reposition 
existing drugs to other diseases offers sizeable reductions in the cost and time of 
drug development and would provide considerable economic benefits to the health 
care system. Additional efforts should be made to pursue this attractive path to 
effective “novel” treatments
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Objectives: The study aims to assess general public awareness towards issues 
related to medication safety in Quetta City, Pakistan. MethOds: A cross-sectional 
copayment amount [41.2% with an increase in generic copayment amount; 74.5% 
with an increased in preferred brand copayment amount; 68.5% with an increase 
in non-preferred brand copayment amount]. cOnclusiOns: 12% of continuously 
enroll beneficiaries experienced benefit design changes that could impact prescrip-
tion utlization and adherence measures. Most of them experienced an increased 
in copayment amount, especially for brand name formulary drugs. Benefit design 
should be incorporated into prescription utilization and adherence studies to more 
accurately estimate these measures.
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Objectives: Several jurisdictions assess the relative clinical effectiveness of new 
therapeutic agents compared to existing products and assign rankings of thera-
peutic improvement. These rankings influence and sometimes determine the 
potential pricing of the product in the respective jurisdiction. This study sought 
to compare the level of therapeutic improvement assessments in three jurisdic-
tions and discuss the parameters leading to any differences observed in level of 
therapeutic improvement rankings. MethOds: Efforts were taken to standardize 
the level of therapeutic ranking systems of Canada, France and Germany to have 
comparable levels of therapeutic improvement. We identified 128 unique substances 
reviewed by Canada’s Patented Medicines Price Review Board (PMPRB) between 
2011 and 2013 for which level of therapeutic improvement rankings were assigned. 
Of these, 18 were also reviewed by the Haute-Autorité de Santé (HAS) in France and 
the Federal Joint Committee (GB-A) in Germany. The level of therapeutic improve-
ment rankings were observed in each jurisdiction to assess concurrence among the 
organizations. Results: Preliminary results indicated that there was concurrence 
in the level of therapeutic improvement rankings across the jurisdictions with most 
products receiving low levels of therapeutic improvement (n= 13). cOnclusiOns: 
Overall, concurrence was observed among the agencies’ level of therapeutic 
improvement rankings for the 18 drugs commonly evaluated. Elements such as a 
review’s timing and order, the primary indication and relevant comparators identi-
fied in the therapeutic area by each jurisdiction are important to understand dis-
crepancies in level of therapeutic improvement suggested. Discussion surrounding 
limitations of standardization is necessary to inform results.
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Objectives: The adoption of elective biomarker tests within US health plans has 
been slow. Without standardized guidelines, payers vary in their coverage policies of 
elective biomarker diagnostics. The aim of this study was to identify factors, includ-
ing the positive predictive value (PPV) of a test, that influence current coverage and 
reimbursement practices of elective biomarker tests amongst US payers. MethOds: 
Independent assessments were conducted with two groups of US payers comprised 
of both medical and pharmacy directors from national and regional health plans. 
In October 2013, a focus group of 44 US payers used 7-point Likert scales to evaluate 
hypothetical scenarios involving varying PPVs. In December 2013, 60 US payers were 
surveyed using 7-point Likert scales to categorize factors that influence the coverage 
of elective biomarker diagnostics within their health plans. Elective biomarkers were 
defined as diagnostic tests that are not required as part of the FDA-approved labe-
ling, but may be used in conjunction since evidence demonstrates that test results 
may determine treatment choices and/or outcomes. Chi-squared analyses are in 
progress to observe differences in responses between the two independent payer 
groups, medical and pharmacy directors, as well as national and regional health 
plans. Results: Based on focus group results, 6 (13.6%), 13 (29.5%), 31 (70.5%), and 
40 (90.1%) US payers were more likely to cover biomarker tests as PPV increased from 
20%, 40%, 60% and 80%, respectively. 52 (86.6%) surveyed payers rated the ability to 
predict the effectiveness of a particular therapy, and 42 (70.0%) rated the ability to 
reduce the frequency of other clinical tests as the main factors influencing coverage 
decisions. cOnclusiOns: In lieu of standardized guidelines, this research indicates 
that the more accurate and effective the biomarker test is at determining treatment 
choices and/or outcomes, the more likely it will be covered by US health plans.
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Objectives: Payers are strongly reluctant to value surrogate endpoints (SEP) as 
they carry substantial uncertainty on the final endpoint. However, it seems that SEP 
are common in payment for performance (P4P) agreements. The objective of this 
project was to Identify the proportion of SEP used in P4P and coverage with evidence 
development (CED). MethOds: Market access agreements (MAA) were identified 
from literature review, completed agencies websites, and experts input. P4P and 
CED were selected. Performance endpoints were classified as SEP or hard endpoint 
(HEP). Results: 149 MAA were identified in 13 countries (France, UK, Italy, Sweden, 
Lithuania, Serbia, Slovenia, Germany, Denmark, Portugal, US, Australia, Canada). 39% 
were P4P (individual outcome-based), and 29% were CED (collective outcome-based) 
agreements. The majority of CED endpoints were HEP (92%), such as overall survival, 
decrease in hospitalizations/ prescriptions, delay switch to insulin treatment, real 
world data collection (e.g. long term safety and efficacy, drug conditions of use in 
practice). In contrast, the majority of P4P were SEP (89%), such as assessment of short 
term effectiveness, targeting a short term laboratory value (e.g. decrease in total 
cholesterol levels, HbA1c, etc.). All oncology drugs P4P had SEP performance criteria. 
There were few P4P (14%) with HEP (e.g. fracture, graft rejection for transplant), and 
